Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (451-460 of 476) with videos related to

Pageof 48
Sort By:
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Blood|October 7, 2015
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapseManoj Garg, Yasunobu Nagata, Deepika Kanojia, et al.
The Journal of Clinical Investigation|April 15, 2024
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemiaTobias Suske, Helena Sorger, Gabriele Manhart, et al.
Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.
JCI Insight|December 8, 2022
Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemiaFriedrich Stölzel, Sarah E Fordham, Devi Nandana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic SyndromesMatteo Bersanelli, Erica Travaglino, Manja Meggendorfer, et al.
Blood|September 21, 2022
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemiaEric J Duncavage, Adam Bagg, Robert P Hasserjian, et al.
Blood|November 2, 2022
Germ line DDX41 mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElisabetta Sauta, Marie Robin, Matteo Bersanelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2025
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic SyndromesMatteo Zampini, Elena Riva, Luca Lanino, et al.
Pageof 48

Showing results (451-460 of 476) with videos related to

Sort By:
Pageof 48
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Blood|October 7, 2015
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapseManoj Garg, Yasunobu Nagata, Deepika Kanojia, et al.
The Journal of Clinical Investigation|April 15, 2024
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemiaTobias Suske, Helena Sorger, Gabriele Manhart, et al.
Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.
JCI Insight|December 8, 2022
Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemiaFriedrich Stölzel, Sarah E Fordham, Devi Nandana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic SyndromesMatteo Bersanelli, Erica Travaglino, Manja Meggendorfer, et al.
Blood|September 21, 2022
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemiaEric J Duncavage, Adam Bagg, Robert P Hasserjian, et al.
Blood|November 2, 2022
Germ line DDX41 mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElisabetta Sauta, Marie Robin, Matteo Bersanelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2025
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic SyndromesMatteo Zampini, Elena Riva, Luca Lanino, et al.
Pageof 48